Thieno [3, 2-d] pyrimidine compound containing piperidine amide structure and application of thieno [3, 2-d] pyrimidine compound

By synthesizing thieno[3,2-d]pyrimidine derivatives containing piperidine amide structures, the problem of high toxicity and side effects of existing thieno[3,2-d]pyrimidine antitumor drugs has been solved, and significant inhibitory effects on human lung adenocarcinoma and human liver cancer cells have been achieved, demonstrating good potential for antitumor drug development.

CN118955526AActive Publication Date: 2024-11-15LIAONING UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411019754.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-15
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

Existing thieno[3,2-d]pyrimidine antitumor drugs suffer from significant toxic side effects, unsatisfactory therapeutic effects, and low oral bioavailability in clinical applications. There is a lack of novel, safe, and effective c-Met kinase inhibitors.

Method used

A series of thiophene[3,2-d]pyrimidine derivatives containing piperidine amide structures were designed and synthesized. Their antitumor activity was verified by in vitro activity screening, and they were prepared into pharmaceutically acceptable salts for the preparation of drugs for the treatment and/or prevention of cancer.

Benefits of technology

The synthesized compounds showed significant inhibitory effects on human lung adenocarcinoma cells and human liver cancer cells, demonstrating promising prospects for the development and application of anti-tumor drugs, particularly for the treatment and prevention of lung and liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955526A_ABST
    Figure CN118955526A_ABST
Patent Text Reader

Abstract

The invention relates to a thieno [3, 2-d] pyrimidine compound containing a piperidine amide structure and application of the thieno [3, 2-d] pyrimidine compound, and belongs to the technical field of medicines, the thieno [3, 2-d] pyrimidine compound containing the piperidine amide structure has a structure shown in a general formula (I), and the thieno [3, 2-d] pyrimidine compound can be pharmaceutically added with acid to form salt. Pharmacological activity screening results show that the compound has good antineoplastic activity on human lung adenocarcinoma cell strains A549 and human hepatoma cell strains HepG2, and has good antineoplastic drug development and application prospects. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine, and specifically relates to thieno[3,2-d]pyrimidine derivatives containing a piperidine amide structure represented by general formula (I) and pharmaceutically acceptable salts thereof, and methods for preparing the same and pharmaceutical compositions containing the same. The present invention also relates to the use of the compounds and pharmaceutically acceptable salts thereof in preparing drugs for treating and / or preventing cancer. Background Art

[0002] Cancer (also known as malignant tumors) has always been one of the most common diseases that plague humans. In 2020, there were 19.3 million new cases of cancer and about 10 million deaths worldwide. The incidence and mortality rates of tumors are increasing rapidly. It can be seen that cancer has become one of the major diseases that threaten human life and health. At present, the main anti-tumor treatments include surgical treatment, chemotherapy, and immunotherapy. Among them, chemotherapy is currently the main treatment for malignant tumors, but in clinical applications, existing anti-tumor drugs often show disadvantages such as easy drug resistance and large toxic side effects. Therefore, the development of new, highly effective and low-toxic anti-tumor drugs is of great scientific significance.

[0003] Thienopyrimidine compounds are an important class of heterocyclic compounds with biological activities such as antitumor, antibacterial, antiviral and anti-inflammatory. Among them, thieno[3,2-d]pyrimidine as a dominant skeleton structure is widely used in the field of medicinal chemistry research, especially in the research and development of antitumor drugs. In recent years, the modification of thieno[3,2-d]pyrimidine mother nucleus has become a hot area in the development of new drugs. A variety of thieno[3,2-d]pyrimidine small molecule compounds with antitumor activity have been studied and reported, such as epidermal growth factor receptor (EGFR) inhibitor Olmutinib, p21 protein activated kinase 4 (PAK4) inhibitor PF-03758309, Aurora kinase (Aurora) inhibitor SNS-314, phosphatidylinositol kinase 3 (PI3K) inhibitor Apitolisib, PI3K and histone deacetylase (HDAC) dual inhibitor Fimepinostat and vascular epidermal growth factor receptor (VEGFR) inhibitor. However, the current research on thieno[3,2-d]pyrimidine anti-tumor drugs mainly has the following problems: large toxic and side effects in clinical application, unsatisfactory clinical treatment effects and pharmacokinetic parameters, low oral bioavailability, etc. Therefore, the development of novel, safe and effective new c-Met kinase inhibitors is still a key area of ​​anti-tumor drug research at home and abroad. Summary of the invention

[0004] The purpose of the present invention is to design and synthesize a series of novel thieno[3,2-d]pyrimidine derivatives containing piperidineamide structures. In vitro activity screening shows that the compounds have anti-tumor activity and can be used for the development of anti-tumor drugs. In the prior art, there is no report on the thieno[3,2-d]pyrimidine derivatives containing piperidineamide structures in the present application and their use in anti-tumor drug research.

[0005] To achieve the purpose of the present invention, the present invention provides a thieno[3,2-d]pyrimidine compound containing a piperidine amide structure represented by general formula (I) and a pharmaceutically acceptable salt thereof.

[0006]

[0007] in:

[0008] R is selected from adamantyl, C6-C 10 Aryl or C6-C 10 Heteroaryl, wherein the aryl is substituted by any 1-3 identical or different R1.

[0009] R1 is selected from hydrogen, halogen, C1-C6 alkyl or C1-C6 alkoxy.

[0010] Furthermore, the above-mentioned thieno[3,2-d]pyrimidine compounds containing a piperidine amide structure and pharmaceutically acceptable salts thereof have two types of substructures represented by the general formula (Ia) or (Ib),

[0011]

[0012] in:

[0013] R is selected from adamantyl, phenyl or pyridyl, wherein the phenyl and pyridyl may be substituted by any 1 to 3 identical or different R1.

[0014] R1 is selected from hydrogen, fluorine, chlorine, methyl or methoxy.

[0015] Furthermore, the thieno[3,2-d]pyrimidine compound containing a piperidine amide structure of general formula (Ia) or (Ib) and its pharmaceutically acceptable salt are selected from the following compounds:

[0016] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-phenylpiperidine-4-carboxamide

[0017] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-fluorophenyl)piperidine-4-carboxamide

[0018] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2-fluorophenyl)piperidine-4-carboxamide

[0019] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-chlorophenyl)piperidine-4-carboxamide

[0020] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methylphenyl)piperidine-4-carboxamide

[0021] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methoxyphenyl)piperidine-4-carboxamide

[0022] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(3,4-dimethoxyphenyl)piperidine-4-carboxamide

[0023] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1-adamantyl)piperidine-4-carboxamide

[0024] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2,4-difluorophenyl)piperidine-4-carboxamide

[0025] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-phenylpiperidine-3-carboxamide

[0026] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-fluorophenyl)piperidine-3-carboxamide

[0027] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2-fluorophenyl)piperidine-3-carboxamide

[0028] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-chlorophenyl)piperidine-3-carboxamide

[0029] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methylphenyl)piperidine-3-carboxamide

[0030] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methoxyphenyl)piperidine-3-carboxamide

[0031] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(3,4-dimethoxyphenyl)piperidine-3-carboxamide

[0032] 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1-adamantyl)piperidine-3-carboxamide

[0033] A pharmaceutical composition comprises the above-mentioned thieno[3,2-d]pyrimidine compound containing a piperidine amide structure and a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable excipient.

[0034] Application of the above-mentioned thieno[3,2-d]pyrimidine compounds containing a piperidine amide structure and pharmaceutically acceptable salts or pharmaceutical compositions thereof in the preparation of drugs for treating and / or preventing cancer.

[0035] Furthermore, the cancer is selected from lung cancer and liver cancer.

[0036] Moreover, according to some common methods in the field to which the present invention belongs, the thieno[3,2-d]pyrimidine derivatives containing a piperidine amide structure represented by the general formula (I) of the present invention can form pharmaceutically acceptable salts with acids. Pharmaceutically acceptable addition salts include inorganic acid and organic acid addition salts, and salts with the following acids are particularly preferred: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, etc.

[0037] The beneficial effects of the present invention are:

[0038] The present invention, through in vitro inhibition of human lung adenocarcinoma cell A549 and human liver cancer cell HepG2 activity test, proves that the compound of the present invention has a significant inhibitory effect on human lung adenocarcinoma cells and human liver cancer cells, and is particularly useful for preparing drugs for treating and / or preventing lung cancer and liver cancer. DETAILED DESCRIPTION

[0039] The examples and preparation examples provided below further illustrate and illustrate the compounds of the present invention and their preparation methods. It should be understood that the scope of the following examples and preparation examples does not limit the scope of the present invention in any way. The following examples are intended to illustrate but not to limit the scope of the present invention. The nuclear magnetic resonance hydrogen spectrum of the compound was measured using Bruker ARX-300, ARX-400 or ARX-600, and the mass spectrum was measured using Agilent 6460QQQ; the infrared spectrum of the compound was measured using Perkin-Elmer Spectrumone FT-IR (potassium bromide tablet method), and all reagents used were analytically pure or chemically pure.

[0040] The following synthetic routes describe the preparation of the derivatives of formula (I) of the present invention, all starting materials are prepared by the following synthetic routes, by methods well known to those of ordinary skill in the field of organic chemistry or are commercially available. All final derivatives of the present invention are prepared by the following synthetic routes or by methods analogous thereto, which methods are well known to those of ordinary skill in the field of organic chemistry. All variable factors used in the following synthetic routes are as defined below or as defined in the claims. The synthetic routes are as follows:

[0041]

[0042] Preparation method

[0043] Step A Synthesis of 2,4-dihydroxythieno[3,2-d]pyrimidine (a)

[0044] 76.40 g (1.27 mol) of urea and 40.00 g (254.47 mmol) of methyl 3-aminothiophene-2-carboxylate were mixed thoroughly, heated to 190°C, and melt reacted for 4 h. The reaction mixture was cooled to 120°C, added to 250 mL of 20% NaOH solution while hot, and stirred at room temperature for 1 h. Insoluble matter was removed by filtration, and the filtrate was adjusted to pH 3.0 with 2.0 mol / L hydrochloric acid solution, stirred at room temperature for 0.5 h, and the precipitated solid was filtered, and the filter cake was washed with water until neutral, and vacuum dried at 50°C for 24 h to obtain 34.70 g of off-white solid 2,4-dihydroxythieno[3,2-d]pyrimidine (a), with a yield of 81.1%, mp 102-104°C (literature value: 101-103°C); MS (ESI), m / Z: C6H5N2O2S[M+H] + Theoretical value is 169.01, measured value is 169.10.

[0045] Step B Synthesis of 2,4-dichlorothieno[3,2-d]pyrimidine (b)

[0046] Weigh 35.00 g (208.12 mmol) of 2,4-dihydroxythieno[3,2-d]pyrimidine (a) and add it in batches to 280 mL of stirred phosphorus oxychloride. Reflux overnight. Remove excess phosphorus oxychloride by evaporation under reduced pressure. Slowly add the reaction mixture into stirred ice water and stir at room temperature for 0.5 h. Filter the precipitated solid, wash the filter cake with water until neutral, and dry it at 50°C under reduced pressure for 24 h to obtain 31.20 g of off-white solid 2,4-dichlorothieno[3,2-d]pyrimidine (b), with a yield of 73.1%, mp 138~140°C (literature value: 138.8~139.3°C); MS (ESI), m / Z: theoretical value C6H3Cl2N2S[M+H] + 204.94, measured value 205.10.

[0047] Step C Synthesis of 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-4-carboxylic acid methyl ester (c) and 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-3-carboxylic acid methyl ester (e)

[0048] 6.16 g (30.04 mmol) of 2,4-dichlorothieno[3,2-d]pyrimidine (b), 12.46 g (90.12 mmol) of potassium carbonate, and 5.60 g (39.11 mmol) of methyl 4-piperidinylcarboxylate or methyl 3-piperidinylcarboxylate were added to 60 mL of acetonitrile, and the mixture was refluxed for 10 h. Most of the solvent was removed by evaporation under reduced pressure. 100 mL of water and 80 mL of dichloromethane were added to the remaining mixture for extraction. The dichloromethane layer was separated, and the water layer was extracted with dichloromethane (2×60 mL). The obtained dichloromethane layers were combined and washed with water until neutral. The dichloromethane layer was dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to remove the solvent to obtain a crude product. The crude product was separated by silica gel column chromatography to obtain a white solid. That is: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-4-carboxylic acid methyl ester (c), 6.15 g, yield 65.7%; HRMS (ESI), m / Z: theoretical value C 13 H 15 ClN3O2S[M+H] + 312.0574, found 312.0578. 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-3-carboxylic acid methyl ester (e), 6.88 g, yield 73.5%; HRMS (ESI), m / Z: theoretical value C 13 H 15 ClN3O2S[M+H] + 312.0574, measured value 312.0577.

[0049] Step D Synthesis of 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-4-carboxylic acid (d) and 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-3-carboxylic acid (f)

[0050] 5.00 g (16.04 mmol) of intermediate (c) or intermediate (e), 45 mL of methanol and 15 mL of water were added to a reaction flask, 1.92 g (48.11 mmol) of sodium hydroxide was added under stirring, and the reaction was stirred at room temperature for 18 h. After the reaction was completed, the methanol was removed by concentration under reduced pressure, 80 mL of water was added to the reaction flask, and the mixture was extracted twice with 80 mL of ethyl acetate, the ethyl acetate phase was discarded, and the pH of the aqueous phase was adjusted to 3-4 with concentrated hydrochloric acid. A large amount of white solid precipitated in the solution, which was filtered, and the filter cake was washed with water until neutral. After drying under reduced pressure at 50°C for 24 h, 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-4-carboxylic acid (d) was obtained, 4.27 g, with a yield of 89.4%, HRMS (ESI), m / Z: theoretical value C 12 H 13 ClN3O2S[M+H] + 298.0417, found 298.0418; 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)piperidine-3-carboxylic acid (f), 4.36 g, yield 91.3%; HRMS (ESI), m / Z: theoretical value C 12 H 13 ClN3O2S[M+H] + 298.0417, measured value 298.0420.

[0051] Step E: General method for preparing compounds of formula Ia-Ib

[0052] 0.89 g (3.00 mmol) of intermediate (d) or intermediate (f), substituted aniline or adamantane amine (3.60 mmol), 0.40 g (6.00 mmol) of triethylamine (TEA) and 1.60 g (4.20 mmol) of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) were dissolved in 10 mL of N,N-dimethylformamide (DMF) and the mixture was stirred at room temperature for 12 h. After the reaction is completed, the reaction solution is poured into 50 mL of 20% sodium carbonate solution, and dichloromethane is added for extraction three times, 30 mL each time. The dichloromethane phases are combined, and the dichloromethane phase is washed three times with 20% sodium carbonate solution, 30 mL each time. The dichloromethane phase is then washed three times with saturated brine, 50 mL each time, dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to remove the solvent to obtain a crude product. The crude product is separated by silica gel column chromatography to obtain a white solid 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-substituted piperidine amide (Ia-1~9 and Ib1~8).

[0053] Example 1: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-phenylpiperidine-4-carboxamide (Ia-1): white solid powder, yield 71.4%; 1H NMR (600MHz, DMSO-d6), δ: 9.97 (s, 1H), 8.30 (d, J = 5.5Hz, 1H), 7.60 (d, J = 7.7Hz, 2H), 7.41 (d, J = 5.5Hz, 1H), 7.29 (t, J = 7.9Hz, 2H) ,7.03(t,J=7.4Hz,1H),4.67(d,J=13.4Hz,2H),3.44–3.33(m,2H),2.85–2.70(m,1H),2.01(d,J=10.7Hz,2H),1.80–1.65(m,2H); 13 C NMR (150 MHz, DMSO-d6), δ: 173.03, 163.15, 158.20, 156.57, 139.69, 135.67, 129.14, 124.33, 123.61, 119.66, 112.89, 45.95, 42.75, 28.73; HRMS (ESI), m / Z: theoretical value C 18 H 18 ClN4OS[M+H] + 373.0890, measured value 373.0891.

[0054] Example 2: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-fluorophenyl)piperidine-4-carboxamide (Ia-2): white solid powder, yield 69.3%; 1 H NMR (600MHz, DMSO-d6), δ: 10.04 (s, 1H), 8.30 (d, J = 5.5Hz, 1H), 7.71–7.54 (m, 2H), 7.41 (d, J = 5.5Hz, 1H), 7.13 (t, J = 8. 9Hz,2H),4.67(d,J=13.4Hz,2H),3.37(t,J=12.1Hz,2H),2.83–2.70(m,1H),2.00(d,J=10.7Hz,2H),1.82–1.64(m,2H); 13 C NMR (150 MHz, DMSO-d6), δ: 172.91, 163.15, 158.37 (d, J = 239.4 Hz), 158.19, 156.56, 136.08, 135.67, 124.33, 121.42, 121.36, 115.76, 115.61, 112.89, 45.93, 42.68, 28.70; HRMS (ESI), m / Z: theoretical value C 18 H 17 ClFN4OS[M+H] + 391.0796, measured value: 391.0796.

[0055] Example 3: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2-fluorophenyl)piperidine-4-carboxamide (Ia-3): white solid powder, yield 65.9%; 1 H NMR (600 MHz, DMSO-d6), δ: 9.78 (s, 1H), 8.30 (d, J = 5.5 Hz, 1H), 7.84 (t, J = 8.7 Hz, 1H), 7.41 (d, J = 5.5 Hz, 1H), 7.31–7.21 (m, 1H), 7.20–7.06 (m, 2H), 4.66 (d, J = 13.4 Hz, 2H), 3.38 (d, J = 13.8 Hz, 2H), 3.04–2.86 (m, 1H), 2.02 (d, J = 11.1 Hz, 2H), 1.86–1.60 (m, 2H); HRMS (ESI), m / Z: theoretical value C 18 H 17 ClFN4OS[M+H] + 391.0796, measured value 391.0798.

[0056] Example 4: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-chlorophenyl)piperidine-4-carboxamide (Ia-4): white solid powder, yield 78.4%; 1 H NMR (600MHz, DMSO-d6), δ: 10.18 (s, 1H), 8.27 (d, J = 5.5Hz, 1H), 7.63 (d, J = 8.9Hz, 2H), 7.41 (d, J = 5.5Hz, 1H), 7.36 (d, J = 8 .8Hz,2H),4.68(d,J=13.5Hz,2H),3.35(t,J=12.0Hz,2H),2.87–2.68(m,1H),2.01(d,J=10.9Hz,2H),1.79–1.60(m,2H); 13 C NMR (150 MHz, DMSO-d6), δ: 173.36, 163.00, 158.12, 156.52, 138.42, 135.65, 129.05, 127.33, 124.24, 121.34, 112.86, 45.90, 42.72, 28.64; HRMS (ESI), m / Z: theoretical value C 18 H 17 Cl2N4OS[M+H] + 407.0500, measured value 407.0501.

[0057] Example 5: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methylphenyl)piperidine-4-carboxamide (Ia-5): white solid powder, yield 73.3%; 1 H NMR (600MHz, DMSO-d6), δ: 9.88 (s, 1H), 8.30 (d, J = 5.5Hz, 1H), 7.48 (d, J = 8.4Hz, 2H), 7.41 (d, J = 5.5Hz, 1H), 7.09 (d, J = 8.2Hz, 2 H),4.66(d,J=13.4Hz,2H),3.37(t,J=10.8Hz,2H),2.84–2.67(m,1H),2.24(s,3H),1.99(d,J=10.8Hz,2H),1.82–1.62(m,2H); 13 C NMR (150 MHz, DMSO-d6), δ: 172.79, 163.15, 158.20, 156.57, 137.18, 135.68, 132.48, 129.50, 124.34, 119.69, 112.89, 45.96, 42.71, 28.75, 20.90; HRMS (ESI), m / Z: theoretical value C 19 H 20 ClN4OS[M+H] + 387.1046, measured value 387.1047.

[0058] Example 6: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methoxyphenyl)piperidine-4-carboxamide (Ia-6): white solid powder, yield 78.9%; 1H NMR (600MHz, DMSO-d6), δ: 9.83 (s, 1H), 8.30 (d, J = 5.5Hz, 1H), 7.51 (d, J = 9.0Hz, 2H), 7.41 (d, J = 5.5Hz, 1H), 6.87 (d, J = 9.0H 13C NMR (150 MHz, DMSO-d6), δ: 172.51, 163.14, 158.19, 156.57, 155.60, 135.66, 132.83, 124.33, 121.21, 114.25, 112.88, 55.61, 45.98, 42.64, 28.78; HRMS (ESI), m / Z: theoretical value C19H20ClN4O2S[M+H]+403.0995, found value 403.0997.

[0059] Example 7: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(3,4-dimethoxyphenyl)piperidine-4-carboxamide (Ia-7): white solid powder, yield 76.1%; 1 H NMR (600MHz, DMSO-d6), δ: 9.83 (s, 1H), 8.30 (d, J = 5.5Hz, 1H), 7.41 (d, J = 5.5Hz, 1H), 7.33 (d, J = 2.2Hz, 1H), 7.10 (dd, J = 8.7, 2.2Hz, 1H), 6.87 (d, J = 8.7Hz,1H),4.66(d,J=13.4Hz,2H),3.71(s,3H),3.70(s,3H),3.36(t,J=1 2.2Hz,2H),2.80–2.67(m,1H),1.99(d,J=10.8Hz,2H),1.84–1.63(m,2H); 13 C NMR (150 MHz, DMSO-d6), δ: 172.57, 163.15, 158.20, 156.57, 148.96, 145.20, 135.68, 133.34, 124.33, 112.88, 112.53, 111.54, 104.86, 56.20, 55.79, 45.96, 42.73, 28.76; HRMS (ESI), m / Z: theoretical value C20 H 22 ClN4O3S[M+H] + 433.1101, measured value 433.1104.

[0060] Example 8: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1-adamantyl)piperidine-4-carboxamide (Ia-8): white solid powder, yield 81.0%; 1 H NMR (600MHz, DMSO-d6), δ: 8.28 (d, J=5.5Hz, 1H), 7.39 (d, J=5.5Hz, 1H), 7.30 (s, 1H), 4.60 (d, J= 13.4Hz,2H),3.25(t,J=11.8Hz,2H),2.50–2.43(m,1H),2.13–1.73(m,11H),1.69–1.43(m,8H); 13 C NMR (150 MHz, DMSO-d6), δ: 173.48, 163.10, 158.16, 156.56, 135.61, 124.31, 112.84, 50.97, 46.06, 42.22, 41.46, 36.52, 29.27, 28.94; HRMS (ESI), m / Z: theoretical value C 22 H 28 ClN4OS[M+H] + 431.1672, measured value 431.1675.

[0061] Example 9: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2,4-difluorophenyl)piperidine-4-carboxamide (Ia-9): white solid powder, yield 70.2%; 1 H NMR(600MHz, DMSO-d6), δ:9.79(s,1H),8.29(d,J=5.5Hz,1H),7.76(dd,J=15.3,8.9Hz,1H),7.41(d,J=5.5Hz,1H),7.36–7.23(m,1 H),7.05(t,J=7.9Hz,1H),4.78–4.52(m,2H),3.34(br,J=4.1Hz,2H),2.99–2.80(m,1H),2.01(d,J=10.9Hz,2H),1.83–1.61(m,2H); 13C NMR (150 MHz, DMSO-d6), δ: 173.49, 163.13, 157.37 (d, J = 247.8 Hz), 135.67, 126.58, 124.32, 123.05, 112.89, 111.60, 104.59, 45.93, 41.96, 28.73; HRMS (ESI), m / Z: theoretical value C 18 H 16 ClF2N4OS[M+H] + 409.0701, measured value 409.0702.

[0062] Example 10: 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-phenylpiperidine-3-carboxamide (Ib-1): white solid powder, yield 72.8%; 1 H NMR (600MHz, DMSO-d6), δ: 10.03 (s, 1H), 8.28 (d, J = 5.5Hz, 1H), 7.59 (d, J = 7.7Hz, 2 H),7.40(d,J=5.5Hz,1H),7.30(t,J=7.9Hz,2H),7.05(t,J=7.4Hz,1H),4.68(d,J=1 3.5Hz,1H),4.55(d,J=13.2Hz,1H),3.59–3.43(m,1H),3.38(m,1H),2.78–2.64(m,1 H),2.09(d,J=9.9Hz,1H),2.00–1.89(m,1H),1.88–1.74(m,1H),1.68–1.49(m,1H); 13 C NMR (150 MHz, DMSO-d6), δ: 171.86, 163.18, 158.24, 156.53, 139.42, 135.74, 129.19, 124.32, 123.81, 119.75, 112.92, 48.57, 46.86, 43.51, 28.24, 24.78; HRMS (ESI), m / Z: theoretical value C 18 H 18 ClN4OS[M+H] + 373.0890, measured value 373.0893.

[0063] Example 11: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-fluorophenyl)piperidine-3-carboxamide (Ib-2): white solid powder, yield 71.1%; 1H NMR (600MHz, DMSO-d6), δ: 10.12 (s, 1H), 8.29 (d, J = 5.5Hz, 1H), 7.75–7.56 (m ,2H),7.41(d,J=5.5Hz,1H),7.15(t,J=8.9Hz,2H),4.68(d,J=13.2Hz,1H),4. 54(d,J=13.3Hz,1H),3.57–3.44(m,1H),3.42–3.36(m,1H),2.72–2.60(m,1H) ,2.17–2.02(m,1H),1.98–1.88(m,1H),1.88–1.77(m,1H),1.68–1.51(m,1H); 13 C NMR (150 MHz, DMSO-d6), δ: 171.74, 163.16, 158.46 (d, J = 239.8 Hz), 158.20, 156.51, 135.81, 135.80, 135.74, 124.31, 121.47 (d, J = 7.8 Hz), 115.76 (d, J = 22.2 Hz), 112.89, 48.50, 46.85, 43.41, 28.20, 24.76; HRMS (ESI), m / Z: theoretical value C 18 H 17 ClFN4OS[M+H] + 391.0796, measured value 391.0797.

[0064] Example 12: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2-fluorophenyl)piperidine-3-carboxamide (Ib-3): white solid powder, yield 68.6%; 1 H NMR (600MHz, DMSO-d6), δ: 9.86 (s, 1H), 8.29 (d, J = 5.5Hz, 1H), 7.95–7.73 (m, 1H) ,7.41(d,J=5.5Hz,1H),7.33–7.22(m,1H),7.22–7.10(m,2H),4.66(d,J=12.9Hz, 1H), 4.51 (d, J=13.4Hz, 1H), 3.70–3.46 (m, 1H), 3.40 (t, J=11.4Hz, 1H), 2.93–2. 75(m,1H),2.19–2.01(m,1H),2.00–1.89(m,1H),1.88–1.72(m,1H),1.58(m,1H); 13C NMR (150 MHz, DMSO-d6), δ: 172.34, 163.16, 158.22, 156.51, 154.32 (d, J = 245.1 Hz), 135.73, 126.28 (d, J = 11.6 Hz), 126.02 (d, J = 7.6 Hz), 125.01, 124.80, 124.30, 115.99 (d, J = 19.4 Hz), 112.90, 48.48, 46.85, 42.78, 28.25, 24.70; HRMS (ESI), m / Z: theoretical value C 18 H 17 ClFN4OS[M+H] + 391.0796, measured value: 391.0796.

[0065] Example 13: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-chlorophenyl)piperidine-3-carboxamide (Ib-4): white solid powder, yield 76.9%; 1 H NMR (600MHz, DMSO-d6), δ: 10.20 (s, 1H), 8.29 (d, J = 5.5Hz, 1H), 7.63 (d, J = 8.9 Hz,2H),7.41(d,J=5.5Hz,1H),7.39–7.28(m,2H),4.67(d,J=13.0Hz,1H),4.53 (d,J=13.3Hz,1H),3.61–3.44(m,1H),3.36(t,J=11.7Hz,1H),2.78–2.60(m,1H ),2.25–2.03(m,1H),2.00–1.88(m,1H),1.88–1.75(m,1H),1.70–1.49(m,1H); 13 CNMR (150 MHz, DMSO-d6), δ: 172.03, 163.16, 158.21, 156.50, 138.36, 135.74, 129.11, 127.33, 124.31, 121.26, 112.90, 48.42, 46.85, 43.45, 28.17, 24.74; HRMS (ESI), m / Z: theoretical value C 18 H 17 Cl2N4OS[M+H] + 407.0500, measured value 407.0503.

[0066] Example 14: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methylphenyl)piperidine-3-carboxamide (Ib-5): white solid powder, yield 71.8%; 1H NMR (600MHz, DMSO-d6), δ: 9.96 (s, 1H), 8.29 (d, J = 5.5Hz, 1H), 7.47 (d, J = 8.4Hz ,2H),7.41(d,J=5.5Hz,1H),7.11(d,J=8.3Hz,2H),4.68(d,J=13.2Hz,1H),4.55 (d,J=13.3Hz,1H),3.57–3.41(m,1H),3.37(m,1H),2.73–2.59(m,1H),2.25(s,3 H),2.15–1.99(m,1H),1.98–1.88(m,1H),1.87–1.73(m,1H),1.67–1.43(m,1H); 13 C NMR (150 MHz, DMSO-d6), δ: 171.60, 163.16, 158.19, 156.52, 136.91, 135.75, 132.69, 129.56, 124.32, 119.75, 112.89, 48.58, 46.78, 43.47, 28.27, 24.80, 20.93; HRMS (ESI), m / Z: theoretical value C 19 H 20 ClN4OS[M+H] + 387.1046, measured value 387.1046.

[0067] Example 15: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methoxyphenyl)piperidine-3-carboxamide (Ib-6): white solid powder, yield 81.4%; 1 H NMR (600MHz, DMSO-d6), δ: 9.92 (s, 1H), 8.29 (d, J = 5.5Hz, 1H), 7.59–7.47 (m, 2 H),7.41(d,J=5.5Hz,1H),6.97–6.80(m,2H),4.68(d,J=13.1Hz,1H),4.55(d, J=13.3Hz,1H),3.72(s,3H),3.54–3.41(m,1H),3.37(s,1H),2.70–2.58(m,1H) ),2.16–2.00(m,1H),1.98–1.88(m,1H),1.88–1.74(m,1H),1.69–1.47(m,1H); 13CNMR (150 MHz, DMSO-d6), δ: 171.30, 163.15, 158.18, 156.52, 155.70, 135.74, 132.55, 124.31, 121.27, 114.29, 112.88, 55.62, 48.63, 46.85, 43.41, 28.27, 24.82; HRMS (ESI), m / Z: theoretical value C 19 H 20 ClN4O2S[M+H] + 403.0995, measured value 403.0995.

[0068] Example 16: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(3,4-dimethoxyphenyl)piperidine-3-carboxamide (Ib-7): white solid powder, yield 78.4%; 1 H NMR (600MHz, DMSO-d6), δ: 9.92 (s, 1H), 8.29 (d, J = 5.5Hz, 1H), 7.41 (d, J = 5.5Hz, 1H), 7.32 (d ,J=2.4Hz,1H),7.09(dd,J=8.7,2.4Hz,1H),6.88(d,J=8.7Hz,1H),4.69(d,J=13.2Hz,1H),4. 56(d,J=13.3Hz,1H),3.72(s,3H),3.71(s,3H),3.53–3.40(m,1H),3.33(t,J=12.9Hz,1H),2. 71–2.57(m,1H),2.17–2.00(m,1H),1.99–1.88(m,1H),1.88–1.73(m,1H),1.68–1.47(m,1H); 13 C NMR (150 MHz, DMSO-d6), δ: 171.36, 163.16, 158.18, 156.52, 148.95, 145.30, 135.74, 133.02, 124.32, 112.88, 112.45, 111.62, 104.85, 56.16, 55.78, 48.61, 46.87, 43.48, 28.29, 24.82; HRMS (ESI), m / Z: theoretical value C 20 H 22 ClN4O3S[M+H] + 433.1101, measured value 433.1102.

[0069] Example 17: 1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1-adamantyl)piperidine-3-carboxamide (Ib-8): white solid powder, yield 83.8%; 1 H NMR (600MHz, DMSO-d6), δ: 8.29 (d, J = 5.5Hz, 1H), 7.40 (m, 2H), 4.49 (t, J = 13.7Hz, 2H), 3.34 –3.19(m,2H),2.45–2.30(m,1H),2.08–1.81(m,11H),1.77–1.55(m,7H),1.54–1.37(m,1H); 13 C NMR (150 MHz, DMSO-d6), δ: 172.26, 163.10, 158.09, 156.52, 135.67, 124.30, 112.78, 51.08, 48.87, 46.81, 43.00, 41.40, 36.48, 29.25, 28.37, 24.79; HRMS (ESI), m / Z: theoretical value C 22 H 28 ClN4OS[M+H] + 431.1672, measured value 431.1673.

[0070] Example 18: In vitro anti-tumor cell activity of thieno[3,2-d]pyrimidine compounds containing a piperidineamide structure

[0071] Human lung adenocarcinoma cell line A549 and human liver cancer cell line HepG2 in logarithmic growth phase were selected, and the in vitro anti-tumor activities of the target compounds of Examples 1 to 17 were tested using the MTT method.

[0072] (1) After the cells are revived and passaged 2-3 times to stabilize, use trypsin solution (0.25%) to digest them from the bottom of the culture bottle. Pour the cell digestion solution into a centrifuge tube, and then add culture medium to stop digestion. Centrifuge the centrifuge tube at 800r / min for 10 minutes, discard the supernatant and add 5mL of culture medium, blow and mix the cells, aspirate 10μL of cell suspension and add it to the cell counting plate for counting, and adjust the cell concentration to 104 cells / well. In the 96-well plate, except for A1 well which is a blank well without cells, add 100μL of cell suspension to the rest. Place the 96-well plate in an incubator and culture for 24 hours.

[0073] (2) Dissolve the test sample in 50 μL of dimethyl sulfoxide, then add an appropriate amount of culture medium to dissolve the sample into a 2 mg / mL solution. Then dilute the sample to 20, 4, 0.8, 0.16, and 0.032 μg / mL in a 24-well plate.

[0074] Each concentration was added to 3 wells, and the growth of cells in the two rows and two columns around was greatly affected by the environment, so they were suitable for use as blank cell wells. The 96-well plate was placed in an incubator and cultured for 72 hours.

[0075] The drug-containing culture medium in the 96-well plate was discarded, and the cells were rinsed twice with phosphate buffer solution (PBS). 100 μL of MTT (tetrazolyl) (0.5 mg / mL) was added to each well and placed in the incubator for 4 hours. The MTT solution was discarded and 100 μL of dimethyl sulfoxide was added. The surviving cells and the MTT reaction product formazan were fully dissolved by shaking on a magnetic oscillator, and the results were measured in an ELISA instrument. The IC value of the drug can be obtained by the Bliss method. 50 The results of the inhibitory activity of the compounds on human lung adenocarcinoma A549 and human liver cancer cells HepG2 are shown in Table 1.

[0076] Table 1 Inhibitory activity of compounds on human lung adenocarcinoma A549 and human liver cancer cells HepG2

[0077]

[0078] It can be clearly seen from Table 1 that the compounds of general formula (I) to be protected by the present invention have good inhibitory activity against human lung adenocarcinoma cell line A549 and human liver cancer cell line HepG2 in vitro. This type of compound has good application prospects for the development of anti-tumor drugs.

[0079] Although the present invention has been described in terms of specific embodiments, modifications and equivalents will be apparent to those skilled in the art and are intended to be encompassed within the scope of the present invention.

Claims

1. A thieno[3,2-d]pyrimidine compound containing a piperidineamide structure and a pharmaceutically acceptable salt thereof, characterized in that: It has the general structural formula shown in (I): in: R is selected from adamantyl, C6-C 10 Aryl or C6-C 10 Heteroaryl, wherein the aryl is substituted by any 1 to 3 identical or different R1; R1 is selected from hydrogen, halogen, C1-C6 alkyl or C1-C6 alkoxy.

2. The thieno[3,2-d]pyrimidine compound containing a piperidineamide structure and a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: Having the general structural formula shown in (Ia) or (Ib): in: R is selected from adamantyl, phenyl or pyridyl, and the phenyl or pyridyl is substituted by any 1-3 identical or different R1; R1 is selected from hydrogen, fluorine, chlorine, methyl or methoxy.

3. The thieno[3,2-d]pyrimidine compound containing a piperidineamide structure and a pharmaceutically acceptable salt thereof according to claim 2, characterized in that: The following compounds are present: 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-phenylpiperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-fluorophenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2-fluorophenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-chlorophenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methylphenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methoxyphenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(3,4-dimethoxyphenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1-adamantyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2,4-difluorophenyl)piperidine-4-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-phenylpiperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-fluorophenyl)piperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(2-fluorophenyl)piperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-chlorophenyl)piperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methylphenyl)piperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(4-methoxyphenyl)piperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(3,4-dimethoxyphenyl)piperidine-3-carboxamide 1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1-adamantyl)piperidine-3-carboxamide.

4. A pharmaceutical composition, characterized in that The invention comprises the thieno[3,2-d]pyrimidine compound containing a piperidineamide structure as claimed in claim 1, 2 or 3 and a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable excipient.

5. Use of the thieno[3,2-d]pyrimidine compound containing a piperidineamide structure according to claim 1, 2 or 3 and a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 4 in the preparation of a drug for treating and / or preventing cancer.

6. The use according to claim 5, characterized in that: The cancers are lung cancer and liver cancer.

Citation Information

Patent Citations

  • 2, 4-diamino-thieno [2, 3-d] pyrimidine derivative as well as preparation method and application thereof

    CN104098587A

  • Thieno [3,2-d] pyrimidine derivative containing indole structure and application thereof

    CN109879887A

  • Novel thieno [3,2-d] pyrimidine derivatives and application thereof

    CN110590807A

  • Novel substituted thienopyrimidine compound as well as preparation method and application thereof

    CN118063485A

  • Thienopyrimidine derivative and use thereof

    KR1020180066985A